Lynch & Associates IN Reduces Stake in Johnson & Johnson (NYSE:JNJ)

Lynch & Associates IN cut its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,800 shares of the company’s stock after selling 651 shares during the quarter. Johnson & Johnson makes up approximately 3.1% of Lynch & Associates IN’s investment portfolio, making the stock its 6th largest holding. Lynch & Associates IN’s holdings in Johnson & Johnson were worth $14,715,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Heartwood Wealth Advisors LLC increased its position in Johnson & Johnson by 112.0% during the first quarter. Heartwood Wealth Advisors LLC now owns 8,757 shares of the company’s stock worth $1,385,000 after acquiring an additional 4,627 shares during the period. Duncan Williams Asset Management LLC bought a new position in Johnson & Johnson during the first quarter worth about $512,000. Cullen Investment Group LTD. increased its position in Johnson & Johnson by 2.7% during the first quarter. Cullen Investment Group LTD. now owns 68,585 shares of the company’s stock worth $10,818,000 after acquiring an additional 1,793 shares during the period. CWM LLC increased its position in Johnson & Johnson by 8.3% during the first quarter. CWM LLC now owns 386,640 shares of the company’s stock worth $61,163,000 after acquiring an additional 29,778 shares during the period. Finally, Davis Capital Management increased its position in Johnson & Johnson by 6.2% during the first quarter. Davis Capital Management now owns 9,144 shares of the company’s stock worth $1,443,000 after acquiring an additional 531 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 1.6 %

JNJ opened at $164.14 on Wednesday. The company’s 50 day moving average is $162.70 and its 200-day moving average is $154.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $395.02 billion, a P/E ratio of 10.23, a PEG ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period last year, the company earned $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. TD Securities reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Thursday, October 10th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $174.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.